Atara Biotherapeutics Inc (NASDAQ:ATRA)’s traded shares stood at 1.2 million during the last session, with the company’s beta value hitting 0.69. At the close of trading, the stock’s price was $0.69, to imply a decrease of -0.86% or -$0.01 in intraday trading. The ATRA share’s 52-week high remains $3.08, putting it -346.38% down since that peak but still an impressive 71.01% since price per share fell to its 52-week low of $0.20. The company has a valuation of $89.66M, with an average of 1.35 million shares in intraday trading volume over the past 10 days and average of 3.19 million shares over the past 3 months.
Atara Biotherapeutics Inc (NASDAQ:ATRA) trade information
After registering a -0.86% downside in the last session, Atara Biotherapeutics Inc (ATRA) has traded red over the past five days. The stock hit a weekly high of 0.7500, dropping -0.86% in its intraday price action. The 5-day price performance for the stock is 3.74%, and -8.74% over 30 days. With these gigs, the year-to-date price performance is 35.34%. Short interest in Atara Biotherapeutics Inc (NASDAQ:ATRA) saw shorts transact 11.03 million shares and set a 4.32 days time to cover.
Atara Biotherapeutics Inc (ATRA) estimates and forecasts
Looking at statistics comparing Atara Biotherapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Atara Biotherapeutics Inc (ATRA) shares are -54.34% down over the last 6 months, with its year-to-date growth rate higher than industry average at 19.92% against 13.00%. Revenue is forecast to grow 41.70% this quarter before jumping 48.50% for the next one. The rating firms project that company’s revenue will grow 593.80% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is $6.47 million. Meanwhile, for the quarter ending Jun 2024, a total of 3 analyst(s) estimate revenue growth to $6.93 million.Earnings reports from the last fiscal year show that sales brought in $1.23 million and $3.77 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 427.70% before jumping 83.80% in the following quarter.
ATRA Dividends
Atara Biotherapeutics Inc has its next earnings report out between May 06 and May 10. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Atara Biotherapeutics Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Atara Biotherapeutics Inc (NASDAQ:ATRA)’s Major holders
Atara Biotherapeutics Inc insiders hold 6.35% of total outstanding shares, with institutional holders owning 73.73% of the shares at 78.73% float percentage. In total, 73.73% institutions holds shares in the company, led by Baupost Group, Inc,.(The) LLC. As of Jun 29, 2023, the company held over 9.77 million shares (or 9.67% of shares), all amounting to roughly $15.74 million.
The next major institution holding the largest number of shares is Wasatch Advisors LP with 8.28 million shares, or about 8.19% of shares outstanding. As of the market price on Jun 29, 2023, these shares were worth $13.34 million.
We also have Vanguard Total Stock Market Index Fund and JP Morgan Small Cap Growth Fund as the top two Mutual Funds with the largest holdings of the Atara Biotherapeutics Inc (ATRA) shares. Going by data provided on Jun 29, 2023, Vanguard Total Stock Market Index Fund holds roughly 2.71 million shares. This is just over 2.68% of the total shares, with a market valuation of $4.36 million. Data from the same date shows that the other fund manager holds a little less at 2.46 million, or 2.43% of the shares, all valued at about 3.96 million.
